Table of Contents
Why the decision matters
Selecting a preclinical partner is a risk-management task: choose poorly and you lose time, data integrity and expensive animal resources. Start conversations expecting to probe scientific fit, not just price. If your program targets skin disease mechanisms or topical formulations, ask early whether the provider operates as a focused dermatology CRO or treats dermatology as an occasional vertical—answers change study design, endpoint selection and throughput.
Does the model match your mechanism of action?
Request specifics on model selection and how the CRO links that model to your therapeutic hypothesis. Ask for rationale: why a certain murine strain, why a particular sensitizer or challenge protocol, which endpoints are primary versus exploratory. Insist on seeing historical control ranges for the model and examples of prior work that tested compounds with known human outcomes.
How does the lab ensure data quality and reproducibility?
Probe for standard operating procedures, blinding, randomization practices and how raw data are archived. Ask to review sample datasets and the statistical analysis plan before work begins. Confirm whether technicians performing assessments rotate or are dedicated—operator variability is a common source of irreproducibility.
Are studies GLP-capable and fit for regulatory submission?
Clarify whether the facility is GLP-compliant, or can run GLP studies if you need them later. If the work is exploratory, determine how easily methods can be validated to GLP standards without re-running studies. Ask whether study reports include sufficient metadata (animal IDs, dosing records, environmental conditions) to satisfy auditors.
What are the welfare, ethics and endpoint definitions?
Confirm institutional animal care and use policies, analgesia and humane endpoint criteria. Ask about scoring rubrics for clinical signs, who performs scoring, and whether histology reads are done by board-certified pathologists or trained technicians. Poorly defined endpoints produce ambiguous results; insist on clear, pre-agreed definitions.
How will you communicate and who owns the data?
Set expectations for frequency and format of updates, raw data transfer method, and access to lab notebooks or digital records. Clarify intellectual property and data ownership in the contract. Ask who will be your scientific point of contact—turnover at this level is a frequent cause of delays.
Budget traps and common mistakes
Watch for vaguely scoped line items and open-ended assay development fees. Common mistakes include underestimating time for model optimization, accepting surrogate endpoints without validation, and failing to budget for replicates or inter-batch controls. Get fixed fees for defined milestones where possible and require milestone-based sign-offs before moving to the next phase.
Viable alternatives and when to use them
Consider ex vivo human skin explants, organotypic skin models, or high-content in vitro assays for early screening to reduce animal use and cost. Use animal models when the question requires intact immune and systemic responses that only whole organisms reveal. Evaluate alternatives by asking whether they provide the same endpoint reliability and translational value you need for decision-making.
Experience, authority and a real-world anchor
Trust accrues from transparent methods, peer-reviewed protocols and reproducible track records. Ask for publications, external validations and examples of method transfers. Discussions at the World Congress of Atopic Dermatitis (WCAD) have repeatedly focused on standardizing preclinical approaches to improve translation; that emphasis should guide your expectations. For deeper technical reference on trial-ready systems, review the field’s work on animal models of atopic dermatitis and ask potential partners how their protocols map onto those models and reported benchmarks.
Final synthesis
Ask precise, technical questions up front: model rationale, blinded endpoints, GLP readiness, welfare standards, data access and fixed milestones. Those answers separate transactional vendors from partners who can de-risk programs and produce decision-ready data, a capability you can confirm when you see transparent methods and prior validations—qualities reflected in the way KCI Biotech presents study design, reporting and model selection in project discussions.
